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http://www.biomedcentral.com/1756-0500/7/883RESEARCH ARTICLE Open AccessCo-occurrence of four nucleotide changes
associated with an adult mitochondrial ataxia
phenotype
Ramón Zabalza1, Anssi Nurminen2, Laurie S Kaguni2,3, Rafael Garesse4,5, M Esther Gallardo4,5*
and Belén Bornstein4,6,7*Abstract
Background: Mitochondrial DNA maintenance disorders are an important cause of hereditary ataxia syndrome, and
the majority are associated with mutations in the gene encoding the catalytic subunit of the mitochondrial DNA
polymerase (DNA polymerase gamma), POLG. Mutations resulting in the amino acid substitutions A467T and W748S
are the most common genetic causes of inherited cerebellar ataxia in Europe.
Methods: We report here a POLG mutational screening in a family with a mitochondrial ataxia phenotype. To
evaluate the likely pathogenicity of each of the identified changes, a 3D structural analysis of the PolG protein was
carried out, using the Alpers mutation clustering tool reported previously.
Results: Three novel nucleotide changes and the p.Q1236H polymorphism have been identified in the affected
members of the pedigree. Computational analysis suggests that the p.K601E mutation is likely the major contributing
factor to the pathogenic phenotype.
Conclusions: Computational analysis of the PolG protein suggests that the p.K601E mutation is likely the most
significant contributing factor to a pathogenic phenotype. However, the co-occurrence of multiple POLG alleles
may be necessary in the development an adult-onset mitochondrial ataxia phenotype.
Keywords: POLG, Ataxia, Mitochondrial disorders, MIRASBackground
Disorders that affect the maintenance of mitochondrial
DNA (mtDNA) are characterized in postmitotic tissues
by depletion or multiple deletions in mtDNA [1-3]. To
date, mutations in twelve nuclear-encoded genes have been
described in association with these clinical syndromes [4].
Mutations in one of these, the POLG gene encoding the
catalytic subunit of the mitochondrial DNA polymerase,
DNA polymerase gamma, is the most common nuclear
gene causing mitochondrial disorders. In fact, more than
170 variants have been reported in the DNA polymerase
gamma mutation database [5]. Clinical phenotypes asso-
ciated with POLG mutations are diverse, ranging in* Correspondence: egallardo@iib.uam.es; bbornstein.hpth@salud.madrid.org
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unless otherwise stated.severity from progressive external ophthalmoplegia [6],
to mitochondrial recessive ataxia-syndrome [7-10], to
Alpers–Huttenlocher syndrome [11]. We report here a
familial adult-onset ataxia syndrome, associated with
three novel POLG nucleotide variants. A computational
analysis of PolGA was carried out, and suggests that one
of these is most likely pathogenic.Methods
Patient evaluation
A 67 year-old woman (patient I-1, Figure 1) was referred
to our hospital because of a progressive 15-year history
of ataxia, dysarthria and sensory axonal polyneuropathy.
There was no relevant history of neurological diseases in
the patient’s family. At age 52, the patient developed in-
stability upon walking and paraesthesia in lower limbs,
when no other symptoms were apparent. Clinical examin-
ation at age 67 revealed dysarthria, gait ataxia, hyporeflexial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mutational screening of the POLG gene. a, Pedigree of the family. Affected members with an adult onset mitochondrial ataxia
syndrome are shown by solid symbols. The segregation pattern of the changes identified and the ages of the pedigree members under study are
indicated. b, Identification of mutations in the POLG gene in two patients with mitochondrial ataxia syndrome. Electropherograms are shown
indicating the nucleotide changes identified. c, Amino acid sequence alignments of PolGA that contain the residues D122, K601 and Y837 in
which novel substitutions were identified, and the common polymorphism Q1236H are shown.
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ataxic syndromes. Molecular analyses excluded mutations
in the SCAS, frataxin and x-fragile genes. Nerve conduc-
tion studies (NCS) showed absence of sural sensory action
potentials. Cranial and spinal cord magnetic resonance im-
aging (MRI) displayed atrophy of the cerebellar hemi-
spheres, high signals in the dentatum and thalamus nuclei,
hyperintensities in images of the subcortical white sub-
stance, and supratentorial cortico-subcortical atrophy. Ten
years later, dysarthria was more evident, and cognitive
symptoms were noted. A neuropsychological examination
showed a cortico-subcortical cognitive impairment, with
defects in attention/concentration and memory tests. Sub-
sequently, she developed a progressive left hemiparesis
related to a non-traumatic subdural haematoma that re-
quired neurosurgical treatment, and began to experience
myoclonus and tonic-clonic seizures. Antiepileptic treat-
ment was started, resulting in complete seizure control.
However, the ataxic gait and dysarthria worsened, and a
weak bilateral palpebral ptosis was observed. A second
NCS revealed a severe sensory axonal neuronopathy.
Presently, the patient requires bilateral support on crutches.
The 61 year-old brother of the female patient showed
a similar clinical presentation over a 7-year period (patientI-3, Figure 1). He began to present with an unsteady walk,
and showed tremor in both legs when standing. In fact, he
had to move to avoid instability with the tremors, suggest-
ing an orthostatic tremor. Additionally, he stated that he
had difficulty in concentrating. Clinical neurological exam-
ination revealed dysarthria, and no deep tendon reflexes
were evident. Analytical blood tests were negative, and
NCS revealed a sensory axonal neuropathy. Neuropsycho-
logical examination showed a normal cognitive function.
MRI displayed high signals in the cerebellar hemispheres,
thalami and spinal cord. Hyperintensities in images of the
subcortical frontal and temporal white substances were also
observed. Five years later, the patient began to show myo-
clonia and tonic-clonic seizures. EEG revealed an alpha
rhythm intercalated with speak-wave paroxysms, predom-
inantly in the frontal lobe. Light stimulation provoked
the appearance of speak-wave discharges with systemic
myoclonia, whereas sound stimulation did not evoke
changes in the EEG. Antiepileptic treatment was initi-
ated and seizures were controlled. At this time, the pa-
tient presents with a sensory axonal neuropathy in the
lower limbs, moderate dysarthria, and an ataxic gait.
The patient does not suffer any functional limitations
and lives independently.
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Samples from patients were obtained in accordance with
the Helsinki Declaration of 1975, as revised in 2000. The
Ethics Committees of the Puerta de Hierro Hospital ap-
proved the study.
Total DNA from patients and relatives was extracted
from blood samples following written informed consent
using a standard phenol-chloroform protocol. Subse-
quently, amplification by PCR of the coding exons and
the flanking intronic sequences of the POLG gene was
carried out. Following PCR amplification, direct sequen-
cing of amplicons was performed on both strands in an
ABI 3730 sequencer (Applied Biosystems; www.applied
biosystems.com; Foster City, CA) using a dye terminator
cycle sequencing kit (Applera, Rockville, MD). Primer se-
quences and PCR conditions are available upon request.
For every sequence variant detected, a cohort of 200 ethnic-
ally matched control subjects was screened using the same
methods. Multiple sequence alignment of PolGA sequences
was performed using the Clustal W2 server (http://www.
ebi.ac.uk/Tools/msa/clustalw2/).
Computational analysis
To evaluate the likely pathogenicity of all the identified
POLG gene sequence variants, a 3D structural analysis
of the PolG protein was performed using the Alpers muta-
tion clustering tool previously described by Euro et al. [12].
Results and discussion
For genomic characterization, exons and flanking intronic
regions of the POLG gene were PCR-amplified and se-
quenced in patients as described previously [10]. Both pa-
tients showed three novel heterozygous nucleotide changes
in the POLG gene: c.364G > T (p.D122Y), c.1801A > G
(p.K601E), and c.2510A >G (p.Y837C), as well as the known
heterozygous polymorphism (c.3708G > T (p.Q1236H). As
an indication of possible pathogenicity, these sequence
variants were not found in 200 chromosomes from con-
trols or in the available databases, and the three amino
acids are evolutionarily conserved (Figure 1). The segrega-
tion pattern of these nucleotide variants in the family
members for which we could obtain samples is shown in
Figure 1.
The PolG enzyme has been studied extensively since
its discovery, and the structure-function relationships
among its domains are now well understood. PolG serves
as the replicative DNA polymerase in mitochondria
and its holoenzyme form comprises a catalytic subunit
(PolGA) and a dimeric accessory subunit (PolGB),
which enhances greatly the activity and processivity of
the holoenzyme [13].
PolGA consists of three structural and functional do-
mains [14]; Figure 2. The N-terminal exonuclease do-
main (exo) contains a 3’-5’ proofreading activity, whichhydrolyzes nucleotides that are misincorporated during
DNA synthesis, increasing several hundredfold the fidel-
ity of mitochondrial DNA replication. The C- terminal
polymerase domain (pol) contains the 5’-3’ DNA poly-
merase active site where incoming nucleotides are poly-
merized onto the nascent primer strand. The central
spacer domain contains the major DNA binding inter-
face of the holoenzyme, as well as the interaction re-
gion for binding the accessory subunit dimer and
putatively, other protein partners of the mitochondrial
DNA replisome.
Recent studies by Euro et al. and Farnum et al. evalu-
ated the published reports of structure-function analyses
of PolG by identifying ‘hot-spots” for pathogenic muta-
tions within its three-dimensional structure [12,15]. Crit-
ical functional regions of the PolGA structure were first
reported as Alpers clusters, and thereafter demonstrated
to represent a total of 136 pathogenic human mutations
that give rise to the entire spectrum of POLG syndromes.
Thus, the clustering model can be used as a guide for
assessing the probability of the deleterious effects of muta-
tions within the PolG structure.
Of the four mutations under study (Figure 2), our struc-
tural analysis suggests that the amino acid change K601E
is the most likely to have deleterious effects. K601E is the
only one of the mutations to have prominent binding part-
ners in the crystal structure (A721 and E616; Figure 3b);
these bonds cannot exist with the charge-reversal muta-
tion from lysine to glutamate. As such, the c.1801A >G
mutation is likely to cause significant structural changes
within the intrinsic processivity (IP) subdomain of the spa-
cer domain (Figure 2). Due to the central location of K601
within the spacer region, these changes are likely to affect
both DNA binding and binding to the proximal accessory
subunit, as well as to potentially hinder other putative
protein-protein interactions within the mitochondrial
replisome.
Residue K601 maps within pathogenic Alpers cluster 2
as defined by Euro et al. [12]. This cluster defines a high-
risk area of the PolG tertiary structure for pathogenic mu-
tations due to altered DNA binding affinity. This in turn
leads to enzyme dysfunction, which results in various hu-
man mitochondrial pathologies ranging from early onset
Alpers syndrome to late onset progressive external oph-
thalmoplegia, depending predominantly on the specific
compound heterozygous mutations carried by the patient.
In fact, ten known pathogenic amino acid substitutions
within the spacer IP-subdomain map within 15 Å of resi-
due K601 (Figure 3b; [15]). Of these ten amino acids, at
least one (A467T) has been reported to present dominant-
like inheritance patterns [16]. Dominant POLG mutations
are rare among the known human pathogenic mutations,
whereas pathogenicity is exhibited typically by recessive
compound heterozygous mutations. The location of K601
Figure 2 Locations of the mutations in the PolG catalytic core with modeled primer template DNA. The four mutations under study are
distributed throughout the structure of PolG catalytic core. Residue K601 is buried within the spacer-region (magenta) IP subdomain. Residue
Y837 is located within a region between the exonuclease (purple) and polymerase domains (pink), at a distance of ~29 Å from the polymerase
active site The location of Y831 on the surface of the enzyme at the opposite side of the thumb helices (H, I) from the putative DNA-binding
channel excludes it from any direct interactions with the polymerase active site. D122 resides in the N-terminal region of the exonuclease domain,
but it is much closer structurally to the polymerase domain and the polymerase active site. Residue Q1236 resides within the C-terminus of the
PolG enzyme. Primer-template DNA was modeled onto the crystal structure of PolG (PDB:3IKM) using the bacteriophage T7 DNA polymerase
crystal structure (PDB:1T8E) as a template.
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phenotype may result from enzyme stalling during
mitochondrial DNA replication. Enzyme stalling dur-
ing replication has been proposed to result in a gradual
mtDNA depletion in post-mitotic tissues, which can
lead to a progressive, late-onset pathology [17]. This
does not however, exclude the possibility that the add-
itional remaining mutations under study contribute to
the deleterious phenotype in our patients.
The c.3708G > T mutation causing the Q1236H amino
acid substitution has been reported to be non-pathogenic
in numerous studies [18], and its lack of conservation
in evolution within the C-terminus of PolG (Figure 1c),
which has no known functionality to date, suggests strongly
that it does not contribute to a pathogenic phenotype. The
dbSNP database reports its frequency in a control popula-
tion of 225 individuals of northern and western European
descent as high as 8.4% [19].
The Y837C mutation lies on the surface of the pol do-
main, in a region of the structure with no known critical
functionality. This location excludes Y837 from any direct
interactions with the residues at the polymerase active site.Furthermore, it does not have any prominent interacting
partners within the PolGA crystal structure, and this re-
gion of the structure exhibits relaxed spatial restrictions
(Figure 3d). Finally, a known, non-pathogenic mutation,
Y831C, lies within the same region of the structure, at an
alpha-carbon distance of 9.6 Å and only six amino acids
away in primary sequence (Figure 1c). Y831C was re-
ported originally as pathogenic [20], but later inter-
preted as non-deleterious [3,21,22]. Altogether these
considerations argue against likely pathogenic effects
of Y837C. At the same time however, the evolutionary
conservation of Y837 gives some credence to a possible
unknown role in enzyme folding or function, leaving
its contribution to a pathogenic phenotype ambiguous.
Amino acid residue D122Y lies on the surface of the PolG
enzyme within 25 Å from the pol active site (Figure 3c).
Its location at the outer periphery of a region providing
access to the pol active site for incoming nucleotides,
makes it the second most likely candidate of the four mu-
tations under study to give rise to deleterious effects. The
relative proximity of D122Y to the pol active site, and to
the region defined as Alpers cluster 1 (pol active site and
Figure 3 Structural details of the four mutations under study. a, ten residues in the spacer IP subdomain that map within 15 Å from K601
are known to have pathogenic human mutations. Yellow coloring shows pathogenic Alpers cluster 2 (DNA binding channel) as defined by Euro
et al. [12]. The most common known POLG mutation, A467T, has been reported to have some dominant-like features [16]. b, K601 interacts with
A721 (2.3 Å) and E616 (2.6 Å) in the crystal structure of PolGA (PDB:3IKM). The ionic interactions depicted by dashed lines cannot exist with the
charge-reversal mutation K601E. c, mutation D122Y lies at the outer periphery of the pol active site access region, within ~25 Å from the active
site. Green coloring shows Alpers cluster 1 residues. Cluster 1 contains all of the conserved Pol family A motifs, as well as all known pathogenic
mutations in the fingers and palm subdomains of the pol domain. The C-terminus, where mutation Q1236H resides, is considerably further away
from the regions that are likely to affect nucleotide polymerization. d, residue Y837 does not form any critical bonds in the PolGA structure. Its
surrounding residues assert only limited spatial pressure, and replacement of this residue with a cysteine does not cause obvious effects on the
tertiary structure. The nearest mutation studied previously, Y831C, is located six amino acids on the N-terminal side in the primary sequence.
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fects in nucleotide polymerization. Cluster 1 contains all
of the conserved family A polymerase motifs, as well as all
the known pathogenic mutations in the palm and fingers
subdomains of the pol domain of the enzyme.
Analysis of evolutionary sequence conservation shows
that with the exception of nematodes, residue D122 is
highly conserved in the eumetazoans and by comparison,
residue Y837 is less well conserved (data not shown).
Because D122 and Y837 are novel mutations that are
not positioned within a known critical region for PolG
functionality, nor do they have prominent interacting
residue partners within the 3D structure, their possible
conformational role in enzyme stability was estimatedusing PON-P [23]. PON-P is a sequence pathogenicity
prediction engine that combines the results of multiple
primary sequence pathogenicity prediction algorithms
into a single consensus prediction. PON-P assigns resi-
due D122Y a very low chance for pathogenicity (8%),
and estimates its ability to predict Y837C pathogenicity
as unreliable (data not shown). An additional element of
uncertainty regarding D122Y are the 69 amino acid resi-
dues of the N-terminus that are missing from the PolG
crystal structure (PDB:3IKM) [14]. These missing amino
acids include the putative mitochondrial import se-
quence as well as a poly-Q stretch, in which variations
have been associated with male infertility [24], though
its role in PolG functionality remains elusive.
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In this study, three novel nucleotide changes and the
known p.Q1236H polymorphism in the POLG gene
have been identified in the two affected members of a
family with a mitochondrial ataxia syndrome. A 3D struc-
tural analysis of the protein argues that the p.K601E muta-
tion is likely to be the most significant contributing factor
to a pathogenic phenotype, although the coexistence of all
the identified POLG changes (allele1: p.K601E and allele 2:
p. Y837C, p.D122Y, Q1236H) may be necessary to produce
the late-onset mitochondrial ataxia phenotype observed.Consent
Written informed consent was obtained from the patient
and each of the patient’s relatives who were involved in
this study for publication of this article and any accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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